The United Kingdom's National Institute for Health and Care Excellence (NICE), which provides value guidance to the National Health Service, has published its final appraisal determination for baricitinib (Olumiant), a Janus kinase inhibitor, recommending use of the drug as an option for treating severe active rheumatoid arthritis.
The United Kingdom (UK)’s National Institute for Health and Care Excellence (NICE), which provides value guidance to the National Health Service, has published its final appraisal determination for baricitinib (Olumiant), a Janus kinase inhibitor, recommending use of the drug as an option for treating severe active rheumatoid arthritis (RA).
NICE recommends the drug together with methotrexate in adults whose RA has not responded adequately to therapy with conventional disease-modifying anti-rheumatic drugs (DMARDs), and as monotherapy for patients who cannot tolerate methotrexate.
The clinical trial data reviewed by NICE demonstrated that combining baricitinib with DMARDs is more effective than treatment with DMARDs alone. The institute also referred to trial evidence that suggested that, in patients who had not previously been treated with DMARDs, baricitinib worked as well when taken alone as it did when taken with a DMARD. Clinical evidence was derived from 4 phase 3, randomized, controlled trials along with 1 long-term safety and tolerability study. NICE noted that the safety profile of baricitinib was similar to that of DMARDs, and that a head-to-head comparison of baricitinib and adalimumab also demonstrated a similarity in safety.
NICE’s evaluation of baricitinib stands in contrast to the US FDA’s opinion of the drug; while baricitinib received its European marketing approval earlier this year, the FDA issued Eli Lilly and Incyte a complete response letter in April, citing a need for additional clinical data that would help to determine an appropriate dose of the therapy.
According to NICE, Eli Lilly arrived at a confidential deal with the UK’s Department of Health to offer baricitinib at a discount to its list price of £10,501 per patient per year. Some have suggested that the recent influx of biosimilar products, including Sandoz’s newly approved Erelzi, into the European RA market explains Lilly’s apparent eagerness to arrive at a price deal with NICE; if new small-molecule drugs such baricitinib are to gain market share, their price points will have to compete with the cost savings provided by biosimilars in the same therapeutic areas.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.